Tridek-One is a private biotechnology company founded in 2018, based on groundbreaking research by our scientific founders at INSERM, Paris on the role of CD31 in the modulation of the immune response.  

CD31 belongs to a family of receptors harboring immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Developing agonists for ‘ITIM receptors’ has the potential to restore the immune balance without immunosuppression. 

Tridek-One demonstrated the ability of CD31 to modulate cells from both the adaptive and innate immune systems which makes it a unique and versatile target across diverse autoimmune and inflammatory disorders. 

Our company is financed by leading European investors and led by an experienced management team supported by renowned advisors.